BCRP

Breast cancer resistance protein (BCRP/ABCG2/MXR/ABCP) is an ATP-dependent efflux transporter, which belongs to the large ATP-binding cassette (ABC) transporter family present on cell membranes, and it is classified into the G subfamily of these transporters. BCRP is expressed in a variety of normal cells and acts as a xenobiotic efflux transporter. BCRP is often associated with cancer chemotherapeutic resistance. BCRP confers multidrug resistance (MDR) to a series of antitumor agents such as Mitoxantrone, Daunorubicin, SN-38, and Topotecan, and often limits the efficacy of chemotherapy.

BCRP physiologically functions as a part of a self-defense mechanism for the organism. It enhances elimination of toxic xenobiotic substances and harmful agents in the gut and biliary tract, as well as through the blood-brain, placental, and possibly blood-testis barriers. BCRP recognizes and transports numerous anticancer drugs including conventional chemotherapeutic and targeted small therapeutic molecules relatively new in clinical use. Thus, BCRP expression in cancer cells directly causes MDR by active efflux of anticancer drugs. Because BCRP is also known to be a stem cell marker, its expression in cancer cells could be a manifestation of metabolic and signaling pathways that confer multiple mechanisms of drug resistance, self-renewal (stemness), and invasiveness (aggressiveness), and thereby impart a poor prognosis. Therefore, blocking BCRP-mediated active efflux may provide a therapeutic benefit for cancers.

BCRP 相关产品（12）

货号	产品名	Cas
PL01058	(S)-ML753286	1699720-85-8
PL03324	Ac32Az19	2760674-72-2
PL02051	Efflux inhibitor-1	1776055-29-8
PL05093	Elacridar	143664-11-3
PC14780	Ko 143	461054-93-3
PL01950	ML230	1776055-05-0
PL02303	ML753286	1699720-89-2
PL04768	PCI 29732	330786-25-9
PL02891	YHO-13177	912287-56-0
PL02892	YHO-13351	1346753-00-1
PL02893	YHO-13351 free base	912288-64-3
PL01543	Zamicastat	1080028-80-3